Jan 11, 2022 / 06:30PM GMT
Tycho W. Peterson - JPMorgan Chase & Co, Research Division - Senior Analyst
All right. Good afternoon, everybody. I'm Tycho Peterson from the life science team. It's my pleasure to introduce our next company this afternoon, Agilent. Just a quick reminder to everybody, if you have questions, you can submit them through the website.
And with that, let me turn it over to Mike.
Michael R. McMullen - Agilent Technologies, Inc. - CEO, President & Director
Hey, thanks, Tycho. It's a real pleasure to be here. Now I'm sure, like all of us, we had hoped to perhaps be doing this conversation face-to-face, but just delighted that you could join us today in this virtual event for me to share with you the updated Agilent story. And it's a really exciting story. We just finished off our 2021 with record performance and entered the 2022 environment with a lot of momentum. So I thought what we would do today is cover 3 topics.
I would like to open up with just a reminder, on the Agilent shareholder value creation model, our results delivered to date
Agilent Technologies Inc at JPMorgan Healthcare Conference Transcript
Jan 22, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers